Intra-Cellular Therapies Inc (NASDAQ:ITCI) was the recipient of some unusual options trading activity on Wednesday. Stock traders acquired 2,023 call options on the company. This is an increase of 1,614% compared to the average daily volume of 118 call options.
ITCI has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Saturday, January 20th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Thursday, March 1st. Cowen restated a “buy” rating and set a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, March 2nd. SunTrust Banks restated a “buy” rating and set a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, March 2nd. Finally, Canaccord Genuity set a $31.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a research note on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. Intra-Cellular Therapies currently has an average rating of “Buy” and an average target price of $28.27.
NASDAQ ITCI opened at $19.46 on Friday. Intra-Cellular Therapies has a 1 year low of $7.85 and a 1 year high of $25.82. The company has a market capitalization of $1,114.39, a price-to-earnings ratio of -9.18 and a beta of 0.59.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). Intra-Cellular Therapies had a negative return on equity of 26.67% and a negative net margin of 39,745.53%. The firm had revenue of $5.06 million during the quarter, compared to analysts’ expectations of $0.05 million. During the same quarter in the prior year, the company earned ($0.64) earnings per share. The business’s revenue for the quarter was down 94.8% compared to the same quarter last year. equities analysts anticipate that Intra-Cellular Therapies will post -3.33 earnings per share for the current fiscal year.
In related news, VP Lawrence J. Hineline sold 49,700 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $20.02, for a total transaction of $994,994.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Michael Halstead sold 25,500 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $18.03, for a total transaction of $459,765.00. Following the sale, the senior vice president now owns 191 shares in the company, valued at $3,443.73. The disclosure for this sale can be found here. 19.80% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in Intra-Cellular Therapies by 21.5% in the 4th quarter. BlackRock Inc. now owns 4,002,920 shares of the biopharmaceutical company’s stock worth $57,962,000 after purchasing an additional 709,048 shares in the last quarter. Millennium Management LLC lifted its stake in Intra-Cellular Therapies by 18.0% in the 4th quarter. Millennium Management LLC now owns 1,454,944 shares of the biopharmaceutical company’s stock worth $21,068,000 after purchasing an additional 221,980 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Intra-Cellular Therapies by 45.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 938,980 shares of the biopharmaceutical company’s stock worth $14,817,000 after purchasing an additional 291,793 shares in the last quarter. Deutsche Bank AG lifted its stake in Intra-Cellular Therapies by 16.4% in the 4th quarter. Deutsche Bank AG now owns 778,776 shares of the biopharmaceutical company’s stock worth $11,274,000 after purchasing an additional 109,636 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Intra-Cellular Therapies by 43.3% in the 4th quarter. Renaissance Technologies LLC now owns 575,300 shares of the biopharmaceutical company’s stock worth $8,330,000 after purchasing an additional 173,700 shares in the last quarter. Institutional investors and hedge funds own 70.47% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/20/intra-cellular-therapies-sees-unusually-high-options-volume-itci.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.